Regarding the use of Tamiflu I follow The Advisory Committee on Immunization Practice guidelines. 

(ACIP) recommends that treatment be considered for the following: 

• Persons with severe, complicated or progressive illness

• Hospitalized persons

• Persons at higher risk for influenza complications:

        - Children <2 years of age (highest risk in children <6 months of age)

        - Adults =65 years of age

        - Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)

        - Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)

        - Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration

        - Pregnant or postpartum women (=2 weeks after delivery)

        - Persons <19 years of age on long-term aspirin therapy

        - American Indians and Alaskan Natives
  
        - Persons who are morbidly obese (BMI =40)

        - Residents of nursing homes or other chronic care facilities 



The ACIP recommends that prophylaxis be considered for the following:

• Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications (see above), and who have not been vaccinated against the circulating strain at the time of the exposure.

• Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment. 

• Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications who cannot be otherwise protected at times of high risk for exposure.

• Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.


There are certainly exceptions to the above rules, however; without having seen the patients it would be hard to make that determination. 






Regarding the use of Tamiflu I follow The Advisory Committee on Immunization Practice guidelines. (ACIP) recommends that treatment be considered for the following: 
• Persons with severe, complicated or progressive illness
• Hospitalized persons
• Persons at higher risk for influenza complications:
        - Children <2 years of age (highest risk in children <6 months of age)
        - Adults =65 years of age
        - Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)
        - Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)
         - Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration
         - Pregnant or postpartum women (=2 weeks after delivery)
         - Persons <19 years of age on long-term aspirin therapy
         - American Indians and Alaskan Natives
          - Persons who are morbidly obese (BMI =40)
          - Residents of nursing homes or other chronic care facilities

The ACIP recommends that prophylaxis be considered for the following:
• Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications (see above), and who have not been vaccinated against the circulating strain at the time of the exposure.
• Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment. 
• Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications who cannot be otherwise protected at times of high risk for exposure.
• Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.


There are certainly exceptions to the above rules, however; without having seen the patients it would be hard to make that determination.